"The global ambulatory EHR market expands with rising digital health adoption, regulatory mandates, and the increasing need for interoperable patient records across all regions."
Lifescience & Healthcare
Demand for personalized medicine and proactive health management propels growth in the global genetic testing market.
The global genetic testing supplement market sits at the intersection of genomics, preventive health and personalized wellness, growing rapidly as consumers and healthcare systems alike embrace insights derived from DNA for diet, supplement and lifestyle recommendations. Regulatory landscapes across regions are increasingly active in the North America genetic tests are regulated under frameworks such as the Food and Drug Administration which grants marketing authorizations for certain in vitro diagnostics, while in Europe the European Food Safety Authority and national bodies govern health claims and data privacy. In the wellness supplement side of the equation where genetic testing is used to tailor nutrigenomic products many markets are moving toward stricter oversight of health claims, data protection and laboratory accreditation. The June 2025 UK initiative allocates GBP 650 million to sequence every newborn, aiming to detect more than 200 rare disorders at birth nhs.uk. Pilot studies show that non-invasive prenatal testing plus ultrasound reaches 88.24% sensitivity for complex chromosomal anomalies, far surpassing conventional protocols. By flagging actionable findings earlier, health systems expect lifetime treatment savings and improved developmental outcomes. Genetic testing provides pregnant women with the benefit of a new type of prenatal test that eliminates the risk of miscarriage. This test involves a simple blood draw from the pregnant woman and can be performed at a very early stage of pregnancy. It is commonly known as non-invasive prenatal testing or cell-free fetal DNA testing.
According to the research report "Global Genetic Testing Supplement Market Outlook, 2030," published by Bonafide Research, the Global Genetic Testing Supplement market was valued at more than USD 18.67 Billion in 2024, and expected to reach a market size of more than USD 45.12 Billion by 2030 with the CAGR of 16.19% from 2025-2030.On the global stage, the genetic testing supplement market is also shaped by strategic mergers, collaborations and cross border trade of testing kits, bio informatics platforms and supplements tied to genomics. The DTC and nutrigenomics arena has seen companies like Genetic Technologies Limited launch its geneType™ multi risk assessment tests globally via its EasyDNA platform, thus expanding the channel for genetic test + supplement programmes. From a raw material and technology sourcing standpoint, laboratories and supplement manufacturers sourcing reagents, kits, sequencing chips and bioinformatics tools must contend with international trade flows like imports of genetic testing consumables such as NGS reagents, microarrays and DNA collection kits are critical, and export markets are expanding for bundles of testing plus supplement services. The collaboration between SOPHiA GENETICS and major clinical centres to provide whole genome analysis platforms worldwide illustrates how data analytics platform trade and services are increasingly global. The market’s consolidation is also underway major acquisitions help create integrated platforms that link genetic test results to supplement or wellness output. The nutrigenomics segment saw launches like the one from Nutrigenomix in Q2?2024 of a new genetic test specifically tailored for personalized nutrition in Asia, illustrating geographic expansion of supplement linked genetic testing. Collaborations such as between Illumina and HaploX to locally manufacture sequencing instruments in China highlight the supply chain and technology deployment side of the market.
The services segment within the global genetic testing supplement market has witnessed the fastest growth, primarily driven by the increasing adoption of personalized medicine, nutrigenomics, and consumer-oriented wellness programs. Unlike consumables and equipment, services encompass genetic analysis, bioinformatics interpretation, personalized report generation, and tailored supplement recommendations, providing end-to-end solutions for both individuals and healthcare providers. The rising prevalence of chronic diseases, genetic disorders, and lifestyle-related conditions has fueled demand for actionable insights derived from DNA analysis, creating a robust market for outsourced genetic services. Direct-to-consumer testing services have surged in popularity, allowing individuals to access genetic risk assessments, ancestry information, and nutrition- or fitness-focused recommendations without the need for clinical visits. Companies such as 23andMe, DNAfit, and Nutrigenomix are capitalizing on this trend by offering subscription-based or one-time genetic testing services, often bundled with personalized supplement suggestions, which cater to the growing health-conscious consumer base seeking proactive and tailored wellness strategies. Additionally, healthcare providers are increasingly integrating genetic services into clinical practice to enhance patient outcomes, enabling precision medicine approaches where supplement regimens and lifestyle interventions are customized according to individual genomic profiles. Technological advancements, particularly in next-generation sequencing and AI-powered bioinformatics platforms, have significantly improved the speed, accuracy, and affordability of genetic analysis services, thereby expanding accessibility across regions.
Next-generation sequencing has emerged as the dominant and fastest-growing technique within the global genetic testing supplement market because it enables comprehensive, rapid, and highly accurate analysis of multiple genes simultaneously, which is critical for both clinical and consumer-focused applications. Unlike traditional Sanger sequencing, NGS can sequence millions of DNA fragments in parallel, dramatically reducing the time and cost per sample while providing far more detailed information about an individual’s genetic makeup. This high-throughput capacity makes it particularly suitable for personalized nutrition and wellness programs, where multiple genes need to be analyzed to recommend targeted supplements, dietary adjustments, and lifestyle interventions based on a person’s unique genomic profile. The scalability of NGS also supports large population studies, allowing companies to generate aggregated data sets that improve the predictive power of nutrigenomics models and supplement recommendations. In addition, advancements in bioinformatics software and AI-driven data interpretation have enhanced the utility of NGS by converting raw genomic data into actionable insights, making it accessible to healthcare providers and direct-to-consumer platforms alike. Regulatory frameworks are also evolving to accommodate the widespread use of NGS in genetic testing, with agencies like the U.S. Food and Drug Administration providing clear guidance for clinical validation, while data privacy regulations such as GDPR in Europe ensure consumer confidence in handling sensitive genetic information. The technique’s versatility across multiple applications ranging from nutrigenomics and metabolic profiling to disease risk prediction and ancestry analysis further reinforces its market dominance.
The Other Clinical segment, encompassing pharmacogenomics, rare disease testing, carrier screening, and other specialized genetic analyses, is experiencing the fastest growth in the global genetic testing supplement market, driven by the increasing focus on precision medicine and personalized healthcare. Pharmacogenomics, in particular, examines how an individual’s genetic profile affects their response to medications, enabling healthcare providers to tailor treatments and avoid adverse drug reactions. This capability has created significant demand for complementary supplement recommendations that can optimize therapeutic outcomes and support overall metabolic health. With the rising prevalence of chronic diseases, multi-drug therapies, and complex health conditions, there is a growing need for genetic insights that extend beyond conventional applications such as oncology or prenatal testing. Direct-to-consumer and clinical service providers are leveraging this trend by offering comprehensive panels that include pharmacogenomic markers, metabolic profiling, and nutrigenomic assessments, often bundled with supplement regimens designed to enhance efficacy and minimize side effects. Technological advancements, particularly in next-generation sequencing (NGS), microarrays, and high-throughput genotyping, have enabled rapid, accurate, and cost-effective analysis of multiple genes simultaneously, facilitating broader adoption of these specialized tests. Companies like 23andMe, GeneDx, and Invitae have expanded their service portfolios to include pharmacogenomic and rare disease panels, integrating these insights with actionable health and wellness recommendations, thereby increasing consumer engagement and market penetration.
Diagnostic laboratories are witnessing rapid growth as the fastest-growing end-use segment in the global genetic testing supplement market, driven by the increasing adoption of precision medicine, personalized wellness programs, and high-throughput genetic testing technologies. Unlike hospitals or clinics, diagnostic laboratories are equipped with advanced sequencing instruments, bioinformatics platforms, and highly specialized personnel, enabling them to process large volumes of samples efficiently while offering a wide array of tests such as pharmacogenomics, nutrigenomics, rare disease screening, oncology testing, and carrier screening. These laboratories often partner with genetic supplement providers to translate genomic insights into actionable supplement recommendations, thereby creating a seamless pathway from testing to personalized health interventions. The rising prevalence of chronic conditions, genetic disorders, and lifestyle-related health issues has intensified the demand for laboratory-based genetic testing services, as both consumers and healthcare providers increasingly seek scientifically validated insights to optimize supplementation and therapeutic strategies. Technological advancements such as next-generation sequencing, microarray technology, and AI-driven data interpretation have further enhanced the efficiency, accuracy, and scalability of diagnostic laboratories, allowing them to deliver rapid results and comprehensive reports that inform personalized supplement plans. Regulatory frameworks play a crucial role in enabling this growth, with agencies such as the U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services providing guidelines and certifications for laboratory operations, while international standards such as ISO 15189 ensure quality and reliability in genetic testing services.
According to the research report "Global Genetic Testing Supplement Market Outlook, 2030," published by Bonafide Research, the Global Genetic Testing Supplement market was valued at more than USD 18.67 Billion in 2024, and expected to reach a market size of more than USD 45.12 Billion by 2030 with the CAGR of 16.19% from 2025-2030.On the global stage, the genetic testing supplement market is also shaped by strategic mergers, collaborations and cross border trade of testing kits, bio informatics platforms and supplements tied to genomics. The DTC and nutrigenomics arena has seen companies like Genetic Technologies Limited launch its geneType™ multi risk assessment tests globally via its EasyDNA platform, thus expanding the channel for genetic test + supplement programmes. From a raw material and technology sourcing standpoint, laboratories and supplement manufacturers sourcing reagents, kits, sequencing chips and bioinformatics tools must contend with international trade flows like imports of genetic testing consumables such as NGS reagents, microarrays and DNA collection kits are critical, and export markets are expanding for bundles of testing plus supplement services. The collaboration between SOPHiA GENETICS and major clinical centres to provide whole genome analysis platforms worldwide illustrates how data analytics platform trade and services are increasingly global. The market’s consolidation is also underway major acquisitions help create integrated platforms that link genetic test results to supplement or wellness output. The nutrigenomics segment saw launches like the one from Nutrigenomix in Q2?2024 of a new genetic test specifically tailored for personalized nutrition in Asia, illustrating geographic expansion of supplement linked genetic testing. Collaborations such as between Illumina and HaploX to locally manufacture sequencing instruments in China highlight the supply chain and technology deployment side of the market.
The services segment within the global genetic testing supplement market has witnessed the fastest growth, primarily driven by the increasing adoption of personalized medicine, nutrigenomics, and consumer-oriented wellness programs. Unlike consumables and equipment, services encompass genetic analysis, bioinformatics interpretation, personalized report generation, and tailored supplement recommendations, providing end-to-end solutions for both individuals and healthcare providers. The rising prevalence of chronic diseases, genetic disorders, and lifestyle-related conditions has fueled demand for actionable insights derived from DNA analysis, creating a robust market for outsourced genetic services. Direct-to-consumer testing services have surged in popularity, allowing individuals to access genetic risk assessments, ancestry information, and nutrition- or fitness-focused recommendations without the need for clinical visits. Companies such as 23andMe, DNAfit, and Nutrigenomix are capitalizing on this trend by offering subscription-based or one-time genetic testing services, often bundled with personalized supplement suggestions, which cater to the growing health-conscious consumer base seeking proactive and tailored wellness strategies. Additionally, healthcare providers are increasingly integrating genetic services into clinical practice to enhance patient outcomes, enabling precision medicine approaches where supplement regimens and lifestyle interventions are customized according to individual genomic profiles. Technological advancements, particularly in next-generation sequencing and AI-powered bioinformatics platforms, have significantly improved the speed, accuracy, and affordability of genetic analysis services, thereby expanding accessibility across regions.
Next-generation sequencing has emerged as the dominant and fastest-growing technique within the global genetic testing supplement market because it enables comprehensive, rapid, and highly accurate analysis of multiple genes simultaneously, which is critical for both clinical and consumer-focused applications. Unlike traditional Sanger sequencing, NGS can sequence millions of DNA fragments in parallel, dramatically reducing the time and cost per sample while providing far more detailed information about an individual’s genetic makeup. This high-throughput capacity makes it particularly suitable for personalized nutrition and wellness programs, where multiple genes need to be analyzed to recommend targeted supplements, dietary adjustments, and lifestyle interventions based on a person’s unique genomic profile. The scalability of NGS also supports large population studies, allowing companies to generate aggregated data sets that improve the predictive power of nutrigenomics models and supplement recommendations. In addition, advancements in bioinformatics software and AI-driven data interpretation have enhanced the utility of NGS by converting raw genomic data into actionable insights, making it accessible to healthcare providers and direct-to-consumer platforms alike. Regulatory frameworks are also evolving to accommodate the widespread use of NGS in genetic testing, with agencies like the U.S. Food and Drug Administration providing clear guidance for clinical validation, while data privacy regulations such as GDPR in Europe ensure consumer confidence in handling sensitive genetic information. The technique’s versatility across multiple applications ranging from nutrigenomics and metabolic profiling to disease risk prediction and ancestry analysis further reinforces its market dominance.
The Other Clinical segment, encompassing pharmacogenomics, rare disease testing, carrier screening, and other specialized genetic analyses, is experiencing the fastest growth in the global genetic testing supplement market, driven by the increasing focus on precision medicine and personalized healthcare. Pharmacogenomics, in particular, examines how an individual’s genetic profile affects their response to medications, enabling healthcare providers to tailor treatments and avoid adverse drug reactions. This capability has created significant demand for complementary supplement recommendations that can optimize therapeutic outcomes and support overall metabolic health. With the rising prevalence of chronic diseases, multi-drug therapies, and complex health conditions, there is a growing need for genetic insights that extend beyond conventional applications such as oncology or prenatal testing. Direct-to-consumer and clinical service providers are leveraging this trend by offering comprehensive panels that include pharmacogenomic markers, metabolic profiling, and nutrigenomic assessments, often bundled with supplement regimens designed to enhance efficacy and minimize side effects. Technological advancements, particularly in next-generation sequencing (NGS), microarrays, and high-throughput genotyping, have enabled rapid, accurate, and cost-effective analysis of multiple genes simultaneously, facilitating broader adoption of these specialized tests. Companies like 23andMe, GeneDx, and Invitae have expanded their service portfolios to include pharmacogenomic and rare disease panels, integrating these insights with actionable health and wellness recommendations, thereby increasing consumer engagement and market penetration.
Diagnostic laboratories are witnessing rapid growth as the fastest-growing end-use segment in the global genetic testing supplement market, driven by the increasing adoption of precision medicine, personalized wellness programs, and high-throughput genetic testing technologies. Unlike hospitals or clinics, diagnostic laboratories are equipped with advanced sequencing instruments, bioinformatics platforms, and highly specialized personnel, enabling them to process large volumes of samples efficiently while offering a wide array of tests such as pharmacogenomics, nutrigenomics, rare disease screening, oncology testing, and carrier screening. These laboratories often partner with genetic supplement providers to translate genomic insights into actionable supplement recommendations, thereby creating a seamless pathway from testing to personalized health interventions. The rising prevalence of chronic conditions, genetic disorders, and lifestyle-related health issues has intensified the demand for laboratory-based genetic testing services, as both consumers and healthcare providers increasingly seek scientifically validated insights to optimize supplementation and therapeutic strategies. Technological advancements such as next-generation sequencing, microarray technology, and AI-driven data interpretation have further enhanced the efficiency, accuracy, and scalability of diagnostic laboratories, allowing them to deliver rapid results and comprehensive reports that inform personalized supplement plans. Regulatory frameworks play a crucial role in enabling this growth, with agencies such as the U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services providing guidelines and certifications for laboratory operations, while international standards such as ISO 15189 ensure quality and reliability in genetic testing services.
Related Press Releases
Sterilization equipment market surge powered by aging global demographics and chronic disease burden
Lifescience & Healthcare
Quick Contacts
Trusted Partners
Latest Press Release
We are friendly and approachable, give us a call.